Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex

Meng, 2010, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line, ACS Nano, 4, 4539, 10.1021/nn100690m Abbasi, 2011, Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer, Med. Res. Rev., 10.1002/med.20244 Diao, 2011, Doxorubicin-loaded PEG-PCL copolymer micelles enhance cytotoxicity and intracellular accumulation of doxorubicin in adriamycin-resistant tumor cells, Int. J. Nanomedicine, 6, 1955 Han, 2011, Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle, Int. J. Pharm., 420, 404, 10.1016/j.ijpharm.2011.09.009 Oza, 2002, Clinical development of P glycoprotein modulators in oncology, Novartis Found. Symp., 243, 103 Rajagopal, 2003, Subcellular localization and activity of multidrug resistance proteins, Mol. Biol. Cell, 14, 3389, 10.1091/mbc.E02-11-0704 van Zon, 2006, Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope, Exp. Cell Res., 312, 245 Ashihara, 2010, Future prospect of RNA interference for cancer therapies, Curr. Drug Targets, 11, 345, 10.2174/138945010790711897 Svenson, 2009, Dendrimers as versatile platform in drug delivery applications, Eur. J. Pharm. Biopharm., 71, 445, 10.1016/j.ejpb.2008.09.023 Platt, 2008, Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor, Mol. Pharm., 5, 474, 10.1021/mp800024g Hyung, 2008, Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment, Biotechnol. Bioeng., 99, 442, 10.1002/bit.21578 Gao, 2010, Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin, J. Pharm. Pharmacol., 62, 393, 10.1211/jpp.62.03.0016 Wei, 2011, H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein, Cancer Chemother. Pharmacol., 67, 1017, 10.1007/s00280-010-1397-7 Reischl, 2009, Drug delivery of siRNA therapeutics: potentials and limits of nanosystems, Nanomedicine, 5, 8, 10.1016/j.nano.2008.06.001 Patil, 2010, The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance, Biomaterials, 31, 358, 10.1016/j.biomaterials.2009.09.048 Santos, 2010, Functionalization of poly (amidoamine) dendrimers with hydrophobic chains for improved gene delivery in mesenchymal stem cells, J. Control. Release, 144, 55, 10.1016/j.jconrel.2010.01.034 Slesina, 2005, Nuclear localization of the major vault protein in U373 cells, Cell Tissue Res., 321, 97, 10.1007/s00441-005-1086-8 Ryu, 2008, On the role of major vault protein in the resistance of senescent human diploid fibroblasts to apoptosis, Cell Death Differ., 15, 1673, 10.1038/cdd.2008.96 Kim, 2006, Crosstalk between Src and major vault protein in epidermal growth factor-dependent cell signalling, FEBS J., 273, 793, 10.1111/j.1742-4658.2006.05112.x Berger, 2009, Vaults and the major vault protein: novel roles in signal pathway regulation and immunity, Cell. Mol. Life Sci., 66, 43, 10.1007/s00018-008-8364-z Herlevsen, 2007, Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes, Mol. Cancer Ther., 6, 1804, 10.1158/1535-7163.MCT-06-0372 Steiner, 2006, Cellular functions of vaults and their involvement in multidrug resistance, Curr. Drug Targets, 7, 923, 10.2174/138945006778019345 van Zon, 2004, Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression, Cancer Res., 64, 4887, 10.1158/0008-5472.CAN-03-3891 Mossink, 2003, Vaults: a ribonucleoprotein particle involved in drug resistance?, Oncogene, 22, 7458, 10.1038/sj.onc.1206947